iBrands Corporation Announces Clinical Trial For Immune Booster Product

LAS VEGAS, June 17, 2020 (GLOBE NEWSWIRE) — iBrands Corporation (OTC: IBRC) (“the Company”), a diversified holding and branding company, announces clinical trial for Quadramune™, the Company’s featured immune boosting nutraceutical product on it’s online store.

The Company’s nutraceutical manufacturer, Therapeutics Solutions International, Inc. (TSOI), announced the initiation of a clinical trial aimed at demonstrating safety and efficacy of its immune-boosting formulation QuadraMune™. Last week the TSOI announced data from a preliminary clinical trial in which four groups of eight volunteers were treated with placebo or escalating doses of QuadraMune™[1]. Elevation of innate immune response activity was observed, together with a decreased responsiveness towards inflammatory stimuli.

These preliminary data were analyzed by the TSOI’s Scientific Advisory Board, who then recommended proceeding to the larger trial. The trial will recruit 500 subjects at risk of SARS-CoV-2 infection, the type of coronavirus which causes COVID-19.

The new clinical trial has been granted ClinicalTrials.gov Identifier: NCT04421391 and is now on the Federal Clinical Trial registry: https://www.clinicaltrials.gov/ct2/show/NCT04421391

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

About iBrands Farms

iBrands Farms is a vertically integrated agribusiness focused on the production of hemp derived products with naturally occurring cannabinoids along with other nutraceutical products. Our mission is to efficiently deliver the highest quality products to our customers, both retail and B2B.

The company can be found at www.ibrandsfarms.com

About iBrands Corporation

iBrands Corporation, Inc. is a holding and branding company that acquires and operates niche market brands that have unique market positions within sectors that demonstrate return on investment potential. Business partnerships throughout the United States and Canada provide our brands many markets to expand into and produce consistently high growth rates for the next decade.

The company can be found at: www.ibrandscorporation.com

Safe Harbor Statement
This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company’s ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company’s suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.

Sources:

[1] https://www.clinicaltrials.gov/ct2/show/NCT04421391

CONTACT: For more information please contact:

investorrelationsdesk@gmail.com